Identification of Biomarkers for Early Detection of Pancreatic Cancer
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is examining blood samples from patients with cancer to identify biomarkers that may help in the early detection of pancreatic cancer.
|Pancreatic Cancer||Genetic: protein expression analysis Other: laboratory biomarker analysis Other: mass spectrometry Other: surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Michigan Center for Pancreatic Cancer Molecular Diagnosis: The Serum Protein Microarray Project|
- Identification of specific proteins of interest to evaluate for their potential role as markers for pancreatic cancer [ Time Frame: Upon collection when patient agrees to provide a one time venous blood collection ]
- Analysis of serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis [ Time Frame: After separation from the plasma ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||February 2005|
|Study Completion Date:||April 2011|
|Primary Completion Date:||November 2009 (Final data collection date for primary outcome measure)|
Genetic: protein expression analysis
- Identify specific proteins of interest to evaluate for their potential role as markers for pancreatic cancer.
- Analyze serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis.
OUTLINE: Blood from patients is collected prior to treatment. Plasma proteins are analyzed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF/MS) and/or electrospray mass spectrometry (ESI/MS).
PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00897494
|United States, Michigan|
|Barbara Ann Karmanos Cancer Institute|
|Detroit, Michigan, United States, 48201-1379|
|Principal Investigator:||Fazlul Sarkar, MD||Barbara Ann Karmanos Cancer Institute|